Kaleido Biosciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 23.09 million compared to USD 23.13 million a year ago. Basic loss per share from continuing operations was USD 0.54 compared to USD 0.65 a year ago.
For the nine months, net loss was USD 70.02 million compared to USD 61.6 million a year ago. Basic loss per share from continuing operations was USD 1.68 compared to USD 1.89 a year ago.